Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | NQO1 | P15559 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | P4HB | P07237 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMAD3 | P84022 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3625103 | 0.84 | CYP3A4 (0.51) | CYP3A4NQO1MAPTTP53P4HB | |
| SCHEMBL3621060 | 0.83 | CYP3A4 (0.53) | CYP3A4NQO1MAPTTP53P4HB | |
| SCHEMBL7993658 | 0.77 | KMT2A (0.49) | CYP3A4NQO1MAPTTP53ALDH1A1 | |
| SCHEMBL7431315 | 0.73 | HTR2A (0.55) | CYP3A4NQO1MAPTTP53ALDH1A1 | |
| SCHEMBL8412184 | 0.73 | CYP3A4 (0.50) | CYP3A4MAPK1SMAD3KMT2AMEN1 | |
| SCHEMBL10328415 | 0.72 | CYP3A4 (0.53) | CYP3A4MAPK1KMT2AMEN1CYP2D6 | |
| SCHEMBL7010764 | 0.71 | PDE5A (0.59) | CYP3A4NQO1MAPTTP53ALDH1A1 | |
| SCHEMBL12574161 | 0.69 | CYP1A2 (0.45) | CYP3A4MAPTKMT2AMEN1CYP2D6 | |
| SCHEMBL6454938 | 0.69 | MAPT (0.81) | NQO1MAPTTP53ALDH1A1MAPK1 | |
| SCHEMBL12635176 | 0.69 | NQO1 (0.62) | CYP3A4NQO1MAPTTP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709526-B2 | Use of cyclolignans and new cyclolignans | BIOVITRUM AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-7709526-B2 | Use of cyclolignans and new cyclolignans | BIOVITRUM AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-7709526-B2 | Use of cyclolignans and new cyclolignans | BIOVITRUM AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20060154982-A1 | for treatment of insulin-like growth factor-1 receptor (IGF-1R) dependent diseases such as cancer, psoriasis, arteriosclerosis or is at risk of restenosis of the coronary arteries after vascular surgery | AXELAR AB (SE) | 2006-07-13 | — | — | US | disclosed |
| US-20040167208-A1 | Use or cyclolignans and new cyclolignans | AXELAR AB (SE) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167208-A1 | Use or cyclolignans and new cyclolignans | IGF1R, IGFBP1, INSR | CYP3A4 3909/4885NQO1 4169/4885MAPT 4101/4885 |
| US-20060154982-A1 | for treatment of insulin-like growth factor-1 receptor (IGF-1R) dependent diseases such as cancer, psoriasis, arteriosclerosis or is at risk of restenosis of the coronary arteries after vascular surgery | IGF1R, IGFBP1, IRS1 | CYP3A4 4860/4885NQO1 4793/4885MAPT 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.